BR0312030A - Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii - Google Patents

Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii

Info

Publication number
BR0312030A
BR0312030A BR0312030-9A BR0312030A BR0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A BR 0312030 A BR0312030 A BR 0312030A
Authority
BR
Brazil
Prior art keywords
angiotensin
combination
receptor antagonists
pde5 inhibitors
pde5
Prior art date
Application number
BR0312030-9A
Other languages
English (en)
Portuguese (pt)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR0312030A publication Critical patent/BR0312030A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0312030-9A 2002-06-26 2003-06-16 Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii BR0312030A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0214784.1A GB0214784D0 (en) 2002-06-26 2002-06-26 Novel combination
PCT/IB2003/002657 WO2004002461A2 (en) 2002-06-26 2003-06-16 Combination of pde5 inhibitors with angiotensin ii receptor antagonists

Publications (1)

Publication Number Publication Date
BR0312030A true BR0312030A (pt) 2005-03-22

Family

ID=9939342

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312030-9A BR0312030A (pt) 2002-06-26 2003-06-16 Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii

Country Status (20)

Country Link
EP (1) EP1524996A2 (zh)
JP (1) JP2005531627A (zh)
KR (1) KR20050013156A (zh)
CN (1) CN1662257A (zh)
AR (1) AR040337A1 (zh)
AU (1) AU2003242895A1 (zh)
BR (1) BR0312030A (zh)
CA (1) CA2491002A1 (zh)
GB (1) GB0214784D0 (zh)
GT (1) GT200300124A (zh)
MX (1) MXPA04012569A (zh)
NO (1) NO20050400L (zh)
PA (1) PA8575501A1 (zh)
PE (1) PE20040868A1 (zh)
PL (1) PL375079A1 (zh)
RU (1) RU2004136276A (zh)
TW (1) TW200404546A (zh)
UY (1) UY27863A1 (zh)
WO (1) WO2004002461A2 (zh)
ZA (1) ZA200409532B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
KR100722897B1 (ko) * 2002-07-26 2007-05-31 올림푸스 가부시키가이샤 화상 처리 시스템
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) * 2005-03-31 2006-11-28 Univ Minas Gerais processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
CA2611638C (en) 2005-06-10 2010-08-24 Dong A Pharm. Co. Ltd. Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidinone derivative
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
CA2625153A1 (en) * 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2377531A2 (en) * 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
HU230154B1 (hu) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Eljárás 2-es helyzetben fenil-szubszituenst hordozó imidazo-triazinon-származékok előállítására
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) * 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
CA2419033A1 (en) * 2000-08-11 2002-02-21 Earl Michael Gibbs Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors

Also Published As

Publication number Publication date
PL375079A1 (en) 2005-11-14
EP1524996A2 (en) 2005-04-27
RU2004136276A (ru) 2005-09-10
PE20040868A1 (es) 2004-11-25
AU2003242895A1 (en) 2004-01-19
ZA200409532B (en) 2006-06-28
JP2005531627A (ja) 2005-10-20
WO2004002461A3 (en) 2004-05-13
AR040337A1 (es) 2005-03-30
NO20050400L (no) 2005-03-29
PA8575501A1 (es) 2003-12-30
MXPA04012569A (es) 2005-04-19
TW200404546A (en) 2004-04-01
GT200300124A (es) 2004-03-17
CN1662257A (zh) 2005-08-31
WO2004002461A2 (en) 2004-01-08
CA2491002A1 (en) 2004-01-08
UY27863A1 (es) 2003-12-31
GB0214784D0 (en) 2002-08-07
KR20050013156A (ko) 2005-02-02

Similar Documents

Publication Publication Date Title
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
ECSP066580A (es) 5,7-DIAMINOPIRAZOLO [4,3-d]PIRIMIDINAS CON ACTIVIDAD INHIBIDORA DE LA PDE-5
CY1117108T1 (el) Ιμιδαζοτριαζινες και ιμιδαζοπυριμιδινες ως αναστολeiς κινασης
BRPI0514666A (pt) antagonistas de receptor de endotelina a (eta) em combinação com inibidores de fosfodiestrase 5 (pdes) e usos destes
ATE430747T1 (de) 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren
BRPI0413922A (pt) xantinas de 8-heteroarila substituìda
SV2002000287A (es) Uso de inhibidor de la quinasa dependiente de la ciclina para preparar una composicion farmaceutica util para tratar enfermedades neurodegenerativas
TNSN07385A1 (en) Therapeutic combination in case of benign prostate hyperplasia
NO20076554L (no) Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
ATE400567T1 (de) Kinaseinhibitoren
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
NI201000059A (es) Inhibidores de la cinasa c-fms.
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
IL163777A0 (en) Kinase inhibitors
BR0312030A (pt) Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii
BR0314196A (pt) Inibidores de tgf-beta
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BR0311191A (pt) Combinação
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
ATE390425T1 (de) Xanthin-phosphodiesterase-v-hemmer polymorphe
ATE378568T1 (de) Schulterstützenmagazin
SE0100733D0 (sv) Non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.